Progress towards prediction of human pharmacokinetic parameters from in vitro technologies

被引:54
作者
Houston, JB [1 ]
Galetin, A [1 ]
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
关键词
clearance; CYP inhibition potential; drug-drug interactions; in vitro technologies; in vitro-in vivo correlations; prediction of human pharmacokinetics;
D O I
10.1081/DMR-120026870
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review provides an academic view of the current status on using in vitro systems for the prediction of human in vivo drug clearance and inhibition interaction potential. It stresses that although in vitro technology continues to develop in an impressive way and expectations are high within the pharmaceutical industry, the potential of prediction process is yet to be fully realized. The principles of scaling and modeling in vitro parameters have a sound base and have been validated by using animal tissue. However, it is clear that the comparatively simple standard approach developed and validated in animal systems, results in a high incidence of underprediction for parameters describing clearance and inhibition interaction potential when applied to humans. There are several challenges to our ability to interpret the human in vitro data that can now be so readily generated, in particular, accommodating the unusual kinetic properties characteristic of CYP3A4 substrates, namely, positive and negative cooperativity, in the assessment of inhibition potential.
引用
收藏
页码:393 / 415
页数:23
相关论文
共 48 条
[1]   Is there a toxicological advantage for non-hyperbolic kinetics in cytochrome P450 catalysis? Functional allostery from "distributrve catalysis" [J].
Atkins, WM ;
Lu, WYD ;
Cook, DL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (36) :33258-33266
[2]   RELATIONSHIP BETWEEN ENOXACIN AND CIPROFLOXACIN PLASMA-CONCENTRATIONS AND THEOPHYLLINE DISPOSITION [J].
DAVIS, JD ;
AARONS, L ;
HOUSTON, JB .
PHARMACEUTICAL RESEARCH, 1994, 11 (10) :1424-1428
[3]   FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling [J].
Davit, B ;
Reynolds, K ;
Yuan, R ;
Ajayi, F ;
Conner, D ;
Fadiran, E ;
Gillespie, B ;
Sahajwalla, C ;
Huang, SM ;
Lesko, LJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (09) :899-910
[4]   Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity [J].
Domanski, TL ;
He, YA ;
Khan, KK ;
Roussel, F ;
Wang, QM ;
Halpert, JR .
BIOCHEMISTRY, 2001, 40 (34) :10150-10160
[5]   In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine [J].
Egnell, AC ;
Houston, B ;
Boyer, S .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (03) :1251-1262
[6]  
Ervine CM, 1996, DRUG METAB DISPOS, V24, P211
[7]   Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: Midazolam, testosterone, and nifedipine [J].
Galetin, A ;
Clarke, SE ;
Houston, JB .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (09) :1108-1116
[8]   Quinidine and haloperidol as modifiers of CYP3A4 activity: Multisite kinetic model approach [J].
Galetin, A ;
Clarke, SE ;
Houston, JB .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) :1512-1522
[9]   Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling [J].
He, YA ;
Roussel, F ;
Halpert, JR .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 409 (01) :92-101
[10]   Elucidation of distinct ligand binding sites for cytochrome P450 3A4 [J].
Hosea, NA ;
Miller, GP ;
Guengerich, FP .
BIOCHEMISTRY, 2000, 39 (20) :5929-5939